AEON Biopharma, Inc. (AEON)

AEON Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2023	Dec 31, 2020
Cash & Equivalents	8.44	5.16	-
Cash & Short-Term Investments	8.44	5.16	-
Cash Growth	145.18%	-	-
Other Current Assets	1.82	1.06	-
Total Current Assets	10.26	6.22	-
Net Property, Plant & Equipment	1.37	0.59	-
Other Long-Term Assets	0.03	0.03	0.08
Total Assets	11.66	6.85	0.08
Accounts Payable	3.91	3.39	0.02
Accrued Expenses	5.22	9.66	-
Short-Term Debt	-	-	0.04
Total Current Liabilities	9.13	13.05	59.59
Long-Term Debt	15.17	-	-
Long-Term Leases	1.02	-	-
Other Long-Term Liabilities	2.19	146.84	-
Total Long-Term Liabilities	18.39	146.84	-
Total Liabilities	27.51	159.89	59.59
Common Stock	0.01	0	0
Additional Paid-in Capital	413.28	320.55	24.31
Accumulated Other Comprehensive Income	-	-60.71	-
Retained Earnings	-429.14	-473.6	-3.59
Total Common Shareholders' Equity	-15.85	-213.76	20.72
Shareholders' Equity	-15.85	-153.04	21.41
Total Liabilities & Equity	11.66	6.85	0.08
Total Debt	16.19	0	0.04
Net Cash (Debt)	-7.76	5.16	-0.04
Net Cash Per Share	-1.92	9.99	-
Book Value	-15.85	-213.76	20.72
Book Value Per Share	-3.92	-414.17	-
Tangible Book Value	-15.85	-213.76	20.72
Tangible Book Value Per Share	-3.92	-414.17	-

Updated Aug 12, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q